BBK Worldwide Builds on Tablet Function in Latest Version of Study eBinder

Article

Applied Clinical Trials

BBK Worldwide announced the latest version its Study eBinder

BBK Worldwide announced the latest version its Study eBinder, which addresses more customization for its tablet that study teams use. Version 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff in its proprietary patient recruitment portal, TrialCentralNet (TCN®). The new version also is fully customizable for the sponsor's brand and content.

You can read the full release here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.